The History of Dialysis
’Remain true to your ideals’
Serving patients in Swaziland
Using protons to take on cancer
A little heart at the center of a complex surgery
On duty in disaster zones
More ‘Quality of Life’ in clinics
Ready to help the littlest ones
Making mistakes to avoid them
"I want to help others, so they won’t give up"
A polyclinic in Ghana
From a local pharmacy to a global corporation
Group Outlook 2018
In 2018, we expect to increase Group sales1,2 by 5% to 8% in constant currency. We project Group net income1,3,4 to increase by 6% to 9% in constant currency.
Fresenius Group Overview
- The Health Care Group
-
Stories
-
![]()
The History of Dialysis
-
![]()
’Remain true to your ideals’
-
![]()
Serving patients in Swaziland
-
![]()
Using protons to take on cancer
-
![]()
A little heart at the center of a complex surgery
-
![]()
On duty in disaster zones
-
![]()
More ‘Quality of Life’ in clinics
-
![]()
Ready to help the littlest ones
-
![]()
Making mistakes to avoid them
-
![]()
"I want to help others, so they won’t give up"
-
![]()
A polyclinic in Ghana
-
![]()
From a local pharmacy to a global corporation
-
- Investors
-
Media
![]()
Contact
Matthias Link
Vice President Corporate Communications
T: +49 (0) 6172 608-2872
matthias.link@fresenius.com - Careers
Outlook
- Investors
- Strategy & Outlook
- Outlook
-
Share Price
Data is delayed by 15 minutes.
Share Price Information -
Related Links
-
Library
-
Event
October 30, 2018 - 02:00 PM | Bad Homburg, Germany
Conference Call Q3 2018, Fresenius
-
FAQ
| Targets 20181 | Fiscal year 2017 | |
| Fresenius Group | ||
| Sales growth (in constant currency) | 5% – 8% | € 33,400 million2 |
|
Net income3 growth |
6% – 9%4 | € 1,816 million5 |
| Net income3 growth (in constant currency), excluding Biosimilars |
~10% – 13%6 |
€ 1,859 million7 |
| Fresenius Medical Care | ||
|
Sales growth (in constant currency) |
5% – 7%8 |
€ 17,298 million8 |
| Net income14 growth | 13% – 15%9 | € 1,280 million |
| Fresenius Kabi | ||
| Sales growth (organic) | 4% – 7% | € 6,358 million |
| EBIT growth10 (in constant currency) | -3% – -6% | € 1,177 million |
| EBIT growth11 (in constant currency), excluding Biosimilars |
~2% – 5% |
€ 1,237 million |
| Fresenius Helios | ||
| Sales growth (organic) | 3% – 6%12 | € 8,668 million13 |
| EBIT growth |
7% – 10% | € 1,052 million13 |
| Fresenius Vamed | ||
| Sales growth (organic) | 5% – 10% | € 1,228 million |
| EBIT growth | 5% – 10% | € 76 million |
- 1 Excluding effects of the Akorn, NxStage and Sound Physicians transactions
- 2 Adjusted for IFRS 15 (€ -486 million at Fresenius Medical Care)
- 3 Net income attributable to shareholders of Fresenius SE & Co. KGaA
- 4 Before special items (before transaction-related effects); including expenditures for further development of biosimilars business (€ 43 million after tax in FY / 17 and ~€ 120 million after tax in FY / 18)
- 5 Before special items (before transaction-related effects, before book gain from U.S. tax reform, before FCPA provision)
- 6 Before special items (before transaction-related effects); excluding expenditures for further development of biosimilars business (€ 43 million after tax in FY / 17 and ~€ 120 million after tax in FY / 18)
- 7 Adjusted net income: before transaction-related effects, before expenditures for further development of biosimilars business, before book gain from U.S. tax reform, before FCPA provision
- 8 Reported sales 2017 of € 17,784 million, adjusted for IFRS 15 (€ -486 million)
- 9 2018 including recurring benefits from U.S. tax reform and adjusted for the re-valuation of Sound Physicians’ share-based payment program caused by its announced divestiture
- 10 Before special items (before transaction-related effects); including expenditures for further development of biosimilars business (€ 60 million in FY / 17 and expected expenditures of ~€ 160 million in FY / 18)
- 11 Before special items (before transaction-related effects); excluding expenditures for further development of biosimilars business (€ 60 million in FY / 17 and expected expenditures of ~€ 160 million in FY / 18)
- 12 Organic growth reflects 11 months contribution of Helios Spain
- 13 Helios Spain consolidated for 11 months
- 14 Net income attributable to shareholders of Fresenius Medical Care AG & Co. KGaA
- As of May, 2018
Contact us
Fresenius SE & Co. KGaA
Else-Kröner-Str. 1
61352 Bad Homburg v.d.H.
Germany
T +49 (0) 6172 608-0
pr-fre@fresenius.com
Contact
